ASM Global’s SAVOR Food Division Announces U.S. Winners of World’s Premier Search Competition for Young Culinary and Hospitality Talent
24.8.2023 16:00:00 EEST | Business Wire | Press release
SAVOR, the culinary division of the world’s leading producer of live-event experiences, ASM Global, has announced Marcus Youn, chef from Knife Pleat, Regina Gutierrez, waiter from The French Laundry and Mitchell Coriell, mixologist from Soho House – Malibu the winners of the American round of the renowned World Young Chef Young Waiter (WYCYW) competition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230823913776/en/
Judge/Chef Roland Passot (right) evaluates contestant Marcus Youn during the chef competition of Young Chef Young Waiter USA on Aug. 21, 2023, at the CIA at Copia. Youn would go on to win first place in the competition and heads to Monaco to compete in the world finals in November. (Photo: Andreas Zhou/SAVOR)
Now in its 44th year, WYCYW is the premier competition promoting hospitality as a career choice, aimed at finding the world’s most skilled chefs, waiters and waitresses under the age of 28.
All three winners from YCYW USA will go on to compete in the World Young Chef Young Waiter finals on Nov. 23 and 24 at the Lycée Rainier III in Monaco to showcase their abilities to world-class chefs, hospitality experts and mixologists. A total of 21 contestants from nine countries will face off for the chance to win the world title of best chef, waiter and mixologist under the age of 28 as well as a cash prize of $10,000.
The finals of YCYW USA took place on Aug. 21, 2023, at the prestigious The Culinary Institute of America at Copia (CIA) in Napa, California. Each of the 11 talented young hospitality stars at the finals submitted a video entry to YCYW USA, which was then whittled down by a panel of expert judges, including Roland Passot, propriétaire and chief culinary officer; Adam Busby, certified master chef and general manager of CIA in St. Helena; and more.
These industry veterans also led the in-person judging at the CIA at Copia where finalists were assessed on creativity, innovation, attention to detail and technical ability over an exciting one-day live finale. The USA winners were chosen from a pool of finalists who represented some of the country’s finest establishments, including Knife Pleat, The Surf Club, The French Laundry, Bouchon Bistro, Ad Hoc + Addendum and more.
“We are so proud to host the first-ever YCYW USA competition, as giving these young culinary stars a platform to showcase their skills has always been a priority at SAVOR,” said Shaun Beard, SAVOR’s senior vice president of food and beverage. “During the finale event, not only did we witness remarkable talent from all of the contestants, but we were amazed by their composure, camaraderie, willingness to help and genuine appreciation for each other’s crafts in a high-pressure situation. All competitors have bright and successful futures ahead of them, and we can’t wait to see what they have in store for us next.”
WYCYW aims to highlight the remarkable talent of the finest young professionals building their careers in the industry while championing the skill and passion that hospitality professionals bring to their work. For more information, please visit https://youngchefyoungwaiter.com/.
About SAVOR
SAVOR is the culinary division of ASM Global, the world's leading producer of entertainment experiences, which spans five continents and more than 350 of the world’s most prestigious arenas, stadiums, convention and exhibit centers, and performing arts venues. The team at SAVOR provides top-notch experiences at every event, from the food preparation to the beverage offerings, whether for intimate VIP experiences or banquets with over 20,000 guests. Besides great, authentic chef-driven food, the core elements of SAVOR's food vision include partnerships with local growers, producers and community members; a commitment to using antibiotic-free meats and poultry; and dedication to minimizing impact on the environment through robust sustainability, recycling and composting programs. For more information, please visit savorasmglobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230823913776/en/
Contact information
Carla Schalman
breakwhitelight (for ASM Global)
carla@breakwhitelight.com
310-827-3169
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom